cyrilzakka/clinical-trials huggingface dataset:
Motor and Cognitive Dual Task Performance in Sports

In this study, it is aimed to examine the dual-task performance of soccer referees. For this purpose, it will be investigated whether the motor or cognitive performance of the referees changes when dual-task is assigned and also whether there are differences in dual-task performance between the referees and athletes with similar training program.

In this study, the motor and cognitive dual-task performances of referees will be evaluated. It also will be investigated whether the referees prioritize one of the performances, motor or cognitive, during the dual-task and whether their role in the competition makes a difference compared to athletes. For this purpose, appropriate motor and cognitive tasks were determined by considering the roles of the referees during the competition.

After completing the Demographic Information Form respectively; Edgren Side Step Agility Test as motor performance assessment, Multiple Object Tracking (MOT) as cognitive performance assessment, and finally Dual-Task evaluation using MOT and Edgren Side Step Agility Test will be applied simultaneously. Dual-task costs will be calculated as a percentage of single-task for both motor and cognitive tasks.

Eligibility Criteria:
Inclusion Criteria:

* To be a soccer referee who trains for a total of 5 hours two days a week, takes part in a maximum of two competitions a week and has been actively affiliated with the National Football Federation for at least 1 year,
* Being an athlete with similar to soccer referees in terms of sociodemographic and physical characteristics and training program,
* Being between aged 18-30 years.

Exclusion Criteria:

* Not attending weekly trainings regularly,
* Having had a surgical operation in the last year,
* Having a history of trauma in the last 6 months,
* Not being able to communicate,
* Having uncorrected visual deficit and hearing problem.
A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion

This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study.

This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.

Eligibility Criteria:
Inclusion Criteria:

1. Aged 20-85 years;
2. ECOG score 0-1 points;
3. Patients with UTUC, undergoing radical nephrectomy, pathological staging For pTanyN0M0;
4. Patients voluntarily signed informed consent.

Exclusion Criteria:

1. Obvious cardiopulmonary dysfunction, serious diabetes and other chronic diseases;
2. Obvious chemotherapy contraindications;
3. Patients have a history of other organ malignancies;
4. Combined with tumors of other sites.
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome


Eligibility Criteria:
Inclusion Criteria:

* ≥ 3 criteria for metabolic syndrome National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III criteria)
* Triglyceride (TG) \< 400 mg/dl and Low Density Lipoprotein-Cholesterol (LDL-C) 100 mg/dl to 190 mg/dl
* Written informed consent for participating in the study

Exclusion Criteria:

* Severe renal disease or renal dysfunction
* Chronic liver disease or liver function impairment
* Inflammatory muscle dysfunction or findings of muscle problems
* Severe cardiac failure

Other protocol defined inclusion exclusion criteria may apply
The Comparison of Pilates with Cognitive Functional Therapy in Adults with Chronic Neck Pain

The aim of this study is to compare the effectiveness of Pilates compared with Cognitive Functional Therapy in adults with chronic neck pain.

Firstly, people being informed about the study and those who determine eligibility criteria they written informer consent. After this, the participants will be randomized by a single-blind assessor in a 1:1 ration to pilates exercises and cognitive functional therapy. The participants of both groups will receive therapy twice a week for eight weeks.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-64
* Pain in neck area for more than 3 months
* Pain in NPRS more than 40/100
* Independently mobility (with or without aid), to be capable of participating in a rehabilitation program twice a week

Exclusion Criteria:

* Serious psychological pathology
* Recently surgery on shoulder or neck area (\<6 months)
* Pain relieving procedures such as injection based therapy and day case procedures (e.g. rhizotomy) in the last 3 months
* Pregnancy
* Rheumatologic/inflammatory disease (e.g. rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, Scheuermann's disease)
* Progressive neurological disease (e.g. Multiple Sclerosis, Parkinson's disease, Motor Neuron Disease)
* Unstable Cardiac Conditions
* Red flags disorders (malignancy/cancer, acute traumas like fracture (\<6 months ago) or infection, spinal cord compression/cauda equina)
Effect of Biologic Therapy on Surgical Outcomes for Perforated Crohn's Patients

crohn's disease patients who present by intestinal perforation as the first presentation are hard to deal with. Surgical techniques as anastmosis or diversion stoma and active course of the disease may greatly affect the quality of life. In post-operative period, is the priority to avoid the post operative complications and to improve surgical outcomes or to stop active course of the disease and to induce remission?. So, those patients were classified into two groups. one group will receive biological therapy early post operative and the other group will receive it 2 or 3 months later after surgery and the investigators will compare results between the two groups.


Eligibility Criteria:
Inclusion Criteria:

* patients at or above 18 years old
* patients with perforated bowel diagnosed as Crohn's disease at presentation underwent surgery

Exclusion Criteria:

* patients less than 18 years old
* well known Crohn's disease patients on medical treatment
* associated bowel disease as malignancy and diverticulosis.
MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia

This is a small pilot / feasibility study (Approximately 50 patients) to assess the possibility of clinical implementation of MRI assessment of patients with cystic fibrosis and primary ciliary dyskinesia.

Patients will undergo their standard CT imaging and lung function investigations and additionally will undergo MRI examination. Reports from CT (the current gold standard) and MRI will be assessed for concordance and patient acceptability and examination implementation costs will also be assessed. Novel MRI-based potential markers of CF and PCD disease state will also be assessed.

In this small single site pilot / feasibility study we aim to recruit approximately 50 patients over the age of 6 years with known cystic fibrosis (CF) or primary ciliary dyskinesia (PCD).

Patients will be recruited from routine clinic appointments or at admission for inpatient investigation and/or treatment at the point of referral for computed tomography (CT) examination. If they consent to participation they will undergo MRI examination in addition to their standard clinical CT (within 7 days of the CT scan - on the same day if practicable).

The magnetic resonance imaging (MRI) scans will be anonymised and reported by radiologists, blinded to the CT findings. The reports and scores (Eichinger and Brody2) will then be compared those of the standard CT to assess concordance between the modalities and inter and intra observer variability.

Potential novel biomarkers (pulmonary ventilation and perfusion (non-contrast) and sinus mucus and liver tissue characteristics) will be compared with established markers (including lung clearance index) and known CF mutation / PCD type.

Patients or their carers will also be asked to fill in a short questionnaire comparing the differential patient acceptability of CT and MRI examinations. The cost (time, resources etc) of each examination will be calculated and compared.

Eligibility Criteria:
Inclusion Criteria:

* Known CF or PCD Referred for CT chest

Exclusion Criteria:

* Contraindication to MRI (Pacemaker etc) Unable to stay still for MRI
Efficacy of Dexmedetomidine-Propofol Versus Ketamine-Propofol for Sedation

This study aims to compare efficacy of sedation between Dexmedetomidine-Propofol and Ketamine-Propofol combinations in the upper or lower gastrointestinal system endoscopy. We compare between 2 combinations as regard hemodynamic stability, post operative side effects as occurrence of delirium, nausea, vomiting, headache, hallucination or agitation.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists physical status I to II.
* Age between 18 and 60 years.
* Both sexes.

Exclusion Criteria:

* Having severe heart, lung, liver disease, kidney failure, or bleeding disorder.
* Patients having fever, hypothermia or infection, electrolyte disorders, such as hypokalemia and hypocalcaemia, acid-base disorder, allergy to drugs to be used.
ChatGPT Helping Advance Training for Medical Students: A Study on Self-Directed Learning Enhancement

The goal of this clinical trial is to evaluate the effect of LearnGuide, a custom GPT developed with ChatGPT for supporting self-directed learning (SDL) in medical students. The main questions it aims to answer are:

How does LearnGuide influence SDL skills among medical students? Can LearnGuide improve critical thinking and learning flow as measured by Cornell Critical Thinking Test (CCTT) Level Z score and Global Flow Score (GFS)?

Participants will:

Undergo a two-hour introduction to LearnGuide. Engage in 12 weeks of SDL task-based training with LearnGuide\&amp;#39;s support.

If there is a comparison group: Researchers will compare the group utilizing LearnGuide for SDL and the group without this tool to see if there is a significant difference in SDL skills, critical thinking, and learning flow experiences.


Eligibility Criteria:
Inclusion Criteria:

* Undergraduate and postgraduate students studying at the Second Xiangya Hospital
* with access to ChatGPT

Exclusion Criteria:

* utilization of large language models for learning assistance more than once weekly for a period exceeding 2 months.
Evaluation of Thriving, Substance Use, Mental Health, and Repeat Injury Among Participants in the THRIVE Program

The goal of this observational study is to determine the impact of a hospital-based violence intervention program on a person's capacity to thrive and recurrent intentional injury. The aims of this study are:

1. To evaluate the impact of the HVIP on building personal capacity of youth who have experienced non-fatal violent injuries to thrive using:

   * Established measure changes in positive psychology and clinical metrics
   * A qualitative interview using thematic content analysis
2. Plot the methodology proposed to measure the impact of THRIVE on subsequent injuries using administrative data sources

Participants will complete surveys, participate in a semi-structured interview, and have their rate of recurrent intentional injury tracked over time.

Researchers will compare the rates of intentional reinjury between participants in the THRIVE program and those who present at other hospitals with similar injuries to see if there is a difference in the rate of recurrent intentional injury a 1, 5, and 10 years.


Eligibility Criteria:
Inclusion Criteria:

* ages 14-29
* presentation with an injury due to violence (defined as a gun shot wound, stab wound, blunt or bodily force, inflicted by someone else)
* participant in the THRIVE Program

Exclusion Criteria:

* unable to consent due to language barrier or brain injury
* sexual assault
* child abuse
* self-inflicted injury
* residence \>1 hour from Toronto city limits
Effect of Hypocalcemia on the Outcome of Elderly Major Trauma Patients With Trauma-induced Coagulopathy

Hypocalcaemia is an independent risk factor of TIC in elderly trauma patients. TIC combined with hypocalcemia had worse coagulation function and more serious acidosis.

This 5-year retrospective, observational, single-center study was conducted at the Second Affiliated Hospital of Zhejiang University Medical School (SAHZU, China). Elderly patients with trauma were registered when they were admitted into intensive care unit affiliated to department of Emergency medicine (EICU) since January 2015 and September 2020.The purpose of this study is to elucidate the effect of hypocalcemia on TIC in elderly trauma patients through a single-center retrospective study, so as to further optimize the diagnosis and treatment strategies for TIC in elderly trauma patients.

Eligibility Criteria:
Inclusion Criteria:

* age≥65 years old
* history of trauma

Exclusion Criteria:

* previous anticoagulants or antiplatelet medication;
* Coagulopathy caused by previous underlying diseases;
* Blood products transfused before admission;
* Cardiac arrest on admission;
* Malignant tumor;
* Data incomplete
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.

This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in terms of FEV1 measured at different time-points, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.

Eligibility Criteria:
Inclusion Criteria:

1. Subject must have a ≥6-months diagnosis of stable mild asthma based on National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP EPR3) guidelines (NAEPP EPR3, 2007)
2. Subject must demonstrate an FEV1 ≥1.5L and ≥80% of predicted based on NHANES III predicted values at the pre-challenge/Pre-saline stage of the first screening MBPC

   a. If a subject's FEV1 at the pre-challenge (baseline/Pre-saline) spirometry is \<80%, but ≥70%, the screening visit may be rescheduled one time (visit must take place within 7 days)
3. Subject must demonstrate airway responsiveness to methacholine at baseline (pre-albuterol dose) PC20 at ≤8 mg/mL concentration of methacholine (Equivalent to PD20 of ≤513 µg) at the first screening MBPC
4. Subject must have a BMI of ≥18 kg/m2 and ≤35 kg/m2 at screening.

Exclusion Criteria:

1. Subject has a fall in FEV1 at the saline stage ≥10% at the screening MBPC. 2. Subject having FEV1 of less than 1.5L at pre-challenge or saline stage of MBPC at any visit. No re-screening/re-scheduling is allowed for such subjects.

-
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

The LUME-Lung3 study is in 2 parts:

Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.

Phase II - Placebo controlled efficacy study of BIBF 1120 added to standard 3 weekly cycles of gemcitabine and cisplatin therapy in patients with at least Stable Disease after 2 previous courses of the chemotherapy


Eligibility Criteria:
Inclusion criteria:

Run-in Phase I

1. Histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent Non Small Cell Lung Cancer (NSCLC) with squamous cell histology.
2. Measurable disease according to Response Evaluation Criteria in Solid Tumours ( RECIST 1.1).
3. Patient Eastern Cooperative Oncology Group (ECOG) score of 0-1.
4. Male or female patients age = 18 years.
5. Life expectancy of at least three (3) months.
6. Written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines.

   Phase II - in addition to the above criteria:
7. Radiologically-confirmed at least stable disease after 2 prior cycles of cisplatin / gemcitabine chemotherapy.

Exclusion criteria:

1. Prior therapy for advanced or metastatic or recurrent Non Small Cell Lung Cancer (NSCLC). One prior adjuvant, neoadjuvant or adjuvant + neoadjuvant treatment is allowed if at least 12 months have elapsed between the end of the treatment and randomization
2. Prior treatment with other Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (other than bevacizumab)
3. Any contraindications for treatment with gemcitabine and/or cisplatin.
4. Use of any investigational drug within 4 weeks of entering the 1199.82 study.
5. History of major thrombotic or clinically relevant bleeding event in the past 6 months.
6. Significant cardiovascular diseases (i.e. hypertension not controlled by medication.
7. Surgery within 4 weeks (except tumour biopsy) prior randomisation and incomplete wound healing.
8. Active brain metastases
9. Radiotherapy (except extremities) within 3 months prior to baseline imaging and radiotherapy for brain metastasis \< 4 weeks prior baseline imaging.
10. Any other current malignancy or malignancy diagnosed within the past five (5) years.
Comparison of the Effects of TFPB and Anterior QLB on Postoperative Analgesia in Cesarean Section Surgery

This study evaluates the postoperative analgesic effects of transversalis fascia plane block and anterior quadratus lumborum block in patients having cesarean section under general anesthesia. General anesthesia will be performed to all patients for the surgery.

In this study, patients are divided into two groups. After the general anesthesia is performed and cesarean section surgery is over; TFPB block will be performed to patients in Group A ; while anterior QLB block will be performed to patients in Group B. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively. Group A - Patients in group A will have TFPB block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively. Group B - Patients in group B will have anterior QLB block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Being pregnant for at least 37 weeks
* Planning an elective cesarean operation
* Being between the ages of 18-45

Exclusion Criteria:

* American Society of Anesthesiologists (ASA) 3-4 patients with comorbidities (Serious renal, cardiac, hepatic disease)
* Being operated with spinal anesthesia
* Obesity (\> 100 kg, BMI\> 35 kg / m2)
* Contraindication of regional anesthesia (coagulopathy, abnormal international normalized ratio (INR), thrombocytopenia, infection at the injection site)
* Hypersensitivity to local anesthetics or a history of allergy
* Patients with a history of opioid use longer than four weeks
* Patients with psychiatric disorders
* Patients with anatomic deformity
* Patients who do not want to participate
Post Bariatric Surgery Acute Kidney Injury: Incidence and Risk Factors

Bariatric surgery is the most effective means of inducing and maintaining sustained weight loss. Apart from the weight loss effect, bariatric surgery leads to the remission of chronic metabolic disorders such as type 2 diabetes (T2D) and hypertension . Recent studies have shown that bariatric surgery improves renal perfusion and glomerular function and reduces inflammatory markers which can lead to an improvement of microalbuminuria and proteinuria However, acute kidney injury (AKI) can complicate the postoperative course after bariatric surgery. The etiology of AKI after bariatric surgery can be multifactorial and complex in obese population . The preexisting factors such as diabetes, hypertension, and CKD in these patients can additionally worsen the renal insult during the postoperative period . Postoperative AKI is associated with increase morbidity and mortality especially in cases of severe AKI that requires dialysis support . Identifying the high-risk patients for development of postoperative AKI would prevent renal injury. Our aim was to study the incidence and etiology of postoperative AKI after bariatric surgery . Causes of post bariatric surgery AKI include . Pre renal causes :dehydration ( repeated vomiting and diarrhoea)which are common complications post bariatric surgery , haemorrhagic shock (from the site of anastomosis , ulcer ) , septic shock ( leakage , pneumonia) , hypotension and respiratory depression secondary to narcotic overdose. Rena causes: contract induced nephropathy after using CT scan guided drainage of intra abdominal collection post operative, Rhabdomylosis , drug induced nephropathy e.g :using of IV vancomycin for sepsis in ICU .. many causes can lead to AkI post bariatric surgery but the common two causes are dehydration and sepsis .


Eligibility Criteria:
1. Inclusion criteria:

   1. Age more than 18 years old undergo bariatric surgery .
   2. BMI ≥30 : ( BMI = weight in kg / height in m²)
2. Exclusion criteria:

   1. previous kidney diseases(AKI , CKD) .
   2. patients unfit for surgery e.g ( comorbidities : CHD , LCF ) 3. Drugs : (ACE-I , ARBs, and NSAIDS)
A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chance. NNC0662-0419 is a new medicine, which cannot be prescribed by doctors. This is the first time the medicine is being given to humans. The study will last for about 9 months.


Eligibility Criteria:
Inclusion Criteria:

* Male or female (sex at birth)
* Aged 19-55 years (both inclusive) at the time of signing the informed consent.
* Body mass index (BMI) between 27.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
* Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

* Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
* Glycated haemoglobin (HbA1c) greater than or equal to (\>=) 6.5 percent (%) (48 millimoles per mole \[mmol/mol\]) at screening.
* Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
* Amylase greater than or equal to (\>=) 2 times upper limit of normal at screening
* Lipase greater than or equal to (\>=) times upper limit of normal at screening
* Calcitonin greater than or equal to (\>=) 50 nanogram per liter (ng/L) at screening